-

01:29:04 PM

TCON Stock News

TCON - TRACON Pharmaceuticals Inc

09/18/23 8:00 AM

Nasdaq : TCON

clinical triallow float

TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned

TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline

RHEA-AI

positive

09/05/23 4:02 PM

Nasdaq : TCON

conferenceslow float

TRACON Pharmaceuticals Announces Participation at Upcoming Investor Conferences

TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other

RHEA-AI

neutral

08/14/23 4:02 PM

Nasdaq : TCON

earningslow float

TRACON Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other

RHEA-AI

neutral

08/02/23 4:05 PM

Nasdaq : TCON

conferencesearningslow float

TRACON to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 14, 2023

TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other

RHEA-AI

neutral

07/11/23 8:00 AM

Nasdaq : TCON

low float

TRACON Pharmaceuticals Announces Collection of Arbitration Award from I-Mab Biopharma

TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product

RHEA-AI

positive

06/20/23 8:00 AM

Nasdaq : TCON

clinical triallow float

TRACON Pharmaceuticals Announces Positive Results Based on Ongoing Double-Digit Objective Response Rate for Single Agent Envafolimab in the ENVASARC Phase 2 Pivotal Trial

Single Agent Envafolimab ORR Exceeded Futility Rule that will be Applied at the Interim Efficacy Analysis Expected in Q3 Continuing Double-Digit Objective Response Rate (ORR) by Blinded Independent Central Review Achieved to Date in Single Agent Envafolimab Cohort without any > Grade 2 Drug Related

RHEA-AI

positive

06/16/23 8:00 AM

Nasdaq : TCON

conferenceslow float

TRACON Pharmaceuticals to Present at the Maxim Group Healthcare Virtual Conference

TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform

RHEA-AI

neutral

06/15/23 8:00 AM

Nasdaq : TCON

low float

TRACON Pharmaceuticals Announces Enforcement Action to Collect Binding Arbitration Award from I-Mab Biopharma

TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform

RHEA-AI

neutral

06/02/23 8:00 AM

Nasdaq : TCON

conferenceslow float

TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference

TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform

RHEA-AI

neutral

05/30/23 8:00 AM

Nasdaq : TCON

low float

TRACON Pharmaceuticals Announces Poster Presentations for Envafolimab and TRC102 at the 2023 ASCO Annual Meeting

TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to

RHEA-AI

positive

1 2 3 4 5 6 7 8 9 10 Next

TCON Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websitetraconpharma.com
Security nameTRACON Pharmaceuticals Inc
SectorManufacturing
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing

About TRACON Pharmaceuticals Inc

tracon pharmaceuticals, inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (amd). its lead clinical stage products include envafolimab (kn035), an investigational pd-l1 single-domain antibody for the treatment of soft tissue sarcoma. the company's clinical stage products also include de-122, which is in randomized phase iia study for the treatment of wet amd; trc102, which is a small molecule that is in phase ii clinical trial for the treatment of mesothelioma, phase i clinical trial to treat solid tumors, phase i/ii to treat solid tumors and lymphomas, and phase i trial to treat lung cancer; trc253, a small molecule, which is in a phase ii clinical trial for the treatment of metastatic castration-resistant prostate cancer; and tj004309, a cd73 antibody that is in phase i clinical development for the treatment of solid tumors. it has collaboration and license agreements w